Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback